Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12428148 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HSD17B10MEN1USP2HPGD | |
| SCHEMBL6396188 | 0.81 | FLT3 (0.54) | ALDH1A1HSD17B10HPGDMAPTKDM4E | |
| SCHEMBL9288910 | 0.75 | CYP17A1 (0.44) | ALDH1A1HSD17B10KMT2ALMNATBXAS1 | |
| SCHEMBL10118094 | 0.75 | ALDH1A1 (0.54) | ALDH1A1KMT2ALMNATBXAS1KDM4E | |
| SCHEMBL29513389 | 0.74 | HSD17B10 (1.00) | ALDH1A1HSD17B10MEN1USP2HPGD | |
| SCHEMBL8985864 | 0.74 | HSD17B10 (1.00) | ALDH1A1HSD17B10MEN1USP2HPGD | |
| SCHEMBL1186098 | 0.72 | CES2 (0.49) | MEN1HPGDKMT2ALMNATBXAS1 | |
| SCHEMBL12427432 | 0.70 | MEN1 (0.73) | ALDH1A1HSD17B10MEN1USP2HPGD | |
| SCHEMBL3536795 | 0.69 | DHODH (0.42) | ALDH1A1TP53LMNATBXAS1 | |
| SCHEMBL8985899 | 0.69 | ALDH1A1 (0.67) | ALDH1A1HSD17B10MEN1USP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403769-B2 | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403769-B2 | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011103557-A1 | SMALL MOLECULE INHIBITORS OF PFKFB3 AND GLYCOLYTIC FLUX AND THEIR METHODS OF USE AS ANTI-CANCER THERAPEUTICS | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | PFKFB3, PFKFB1, PFKFB2 | ALDH1A1 1970/4885HSD17B10 1711/4885MEN1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.